Abstract
Several new drug targets of anti-atherosclerosis, emerging in the recent years, such as PPAR agonists, cholesteryl ester transfer protein (CETP) inhibitors, infusion of apolipoprotein A-I (apoA-I), liver X receptor (LXR) activators and phospholipid transfer protein (PLTP) inhibitors etc were reviewed.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Apolipoprotein A-I / therapeutic use*
-
Atherosclerosis / drug therapy*
-
Atherosclerosis / metabolism
-
Benzoates / chemistry
-
Benzoates / therapeutic use*
-
Benzylamines / chemistry
-
Benzylamines / therapeutic use*
-
Cholesterol Ester Transfer Proteins / antagonists & inhibitors
-
Cholesterol Ester Transfer Proteins / metabolism
-
DNA-Binding Proteins / agonists
-
DNA-Binding Proteins / metabolism
-
Humans
-
Liver X Receptors
-
Molecular Structure
-
Orphan Nuclear Receptors
-
Oxazines / chemistry
-
Oxazines / therapeutic use*
-
Peroxisome Proliferator-Activated Receptors / agonists
-
Peroxisome Proliferator-Activated Receptors / metabolism
-
Phenylpropionates / chemistry
-
Phenylpropionates / therapeutic use*
-
Quinolines / chemistry
-
Quinolines / therapeutic use*
-
Receptors, Cytoplasmic and Nuclear / agonists
-
Receptors, Cytoplasmic and Nuclear / metabolism
Substances
-
Apolipoprotein A-I
-
Benzoates
-
Benzylamines
-
CETP protein, human
-
Cholesterol Ester Transfer Proteins
-
DNA-Binding Proteins
-
GW 3965
-
Liver X Receptors
-
Orphan Nuclear Receptors
-
Oxazines
-
Peroxisome Proliferator-Activated Receptors
-
Phenylpropionates
-
Quinolines
-
Receptors, Cytoplasmic and Nuclear
-
torcetrapib
-
ragaglitazar